DOP2021000072A - Análogos de proteína tirosina-tirosina y métodos de uso de esta - Google Patents

Análogos de proteína tirosina-tirosina y métodos de uso de esta

Info

Publication number
DOP2021000072A
DOP2021000072A DO2021000072A DO2021000072A DOP2021000072A DO P2021000072 A DOP2021000072 A DO P2021000072A DO 2021000072 A DO2021000072 A DO 2021000072A DO 2021000072 A DO2021000072 A DO 2021000072A DO P2021000072 A DOP2021000072 A DO P2021000072A
Authority
DO
Dominican Republic
Prior art keywords
tyrosine
pyy
methods
analogs
analogues
Prior art date
Application number
DO2021000072A
Other languages
English (en)
Inventor
Anthony Briere Daniel
Christopher Lopes Daniel
Muppidi Avinash
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2021000072A publication Critical patent/DOP2021000072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen análogos de PYY que incluyen modificaciones que aumentan la semivida en comparación con PYY humano, nativo, así como modificaciones adicionales que aumentan la potencia y selectividad para el receptor NPY2. También se describen composiciones farmacéuticas que incluyen uno o más de los análogos de PYY descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se describen métodos para elaborar y usar los análogos de PYY, especialmente para tratar la obesidad y las enfermedades y los trastornos relacionados con la obesidad, tales como diabetes mellitus tipo II.
DO2021000072A 2018-11-01 2021-04-20 Análogos de proteína tirosina-tirosina y métodos de uso de esta DOP2021000072A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754244P 2018-11-01 2018-11-01
US201962793544P 2019-01-17 2019-01-17
PCT/US2019/058259 WO2020092191A1 (en) 2018-11-01 2019-10-28 Protein tyrosine-tyrosine analogs and methods of using the same

Publications (1)

Publication Number Publication Date
DOP2021000072A true DOP2021000072A (es) 2021-05-31

Family

ID=68582448

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000072A DOP2021000072A (es) 2018-11-01 2021-04-20 Análogos de proteína tirosina-tirosina y métodos de uso de esta

Country Status (21)

Country Link
US (2) US11155592B2 (es)
EP (1) EP3873924A1 (es)
JP (2) JP7280949B2 (es)
KR (1) KR102667979B1 (es)
CN (1) CN112888705A (es)
AU (2) AU2019371232B2 (es)
BR (1) BR112021006782A2 (es)
CA (1) CA3118002A1 (es)
CL (1) CL2021001073A1 (es)
CO (1) CO2021005514A2 (es)
CR (1) CR20210192A (es)
DO (1) DOP2021000072A (es)
EC (1) ECSP21030933A (es)
IL (1) IL282177A (es)
MX (1) MX2021004930A (es)
MY (1) MY197530A (es)
PE (1) PE20211466A1 (es)
PH (1) PH12021550964A1 (es)
SG (1) SG11202104161RA (es)
TW (2) TWI749381B (es)
WO (1) WO2020092191A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists
CA3185637A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
CN116710462A (zh) 2021-01-20 2023-09-05 维京治疗公司 用于治疗代谢病症和肝病的组合物和方法
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515533A (ja) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
AU2003201998C1 (en) * 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
WO2004089279A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
EP2279204A1 (en) * 2008-05-16 2011-02-02 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
CA2909045C (en) * 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
MY187047A (en) 2015-06-12 2021-08-27 Novo Nordisk As Selective pyy compounds and uses thereof
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法

Also Published As

Publication number Publication date
JP2023082013A (ja) 2023-06-13
AU2019371232B2 (en) 2022-07-14
WO2020092191A1 (en) 2020-05-07
US20220025009A1 (en) 2022-01-27
SG11202104161RA (en) 2021-05-28
AU2019371232A1 (en) 2021-05-20
US11155592B2 (en) 2021-10-26
CR20210192A (es) 2021-05-18
PH12021550964A1 (en) 2021-11-29
MY197530A (en) 2023-06-21
JP7280949B2 (ja) 2023-05-24
EP3873924A1 (en) 2021-09-08
TW202033544A (zh) 2020-09-16
KR102667979B1 (ko) 2024-05-24
US11820803B2 (en) 2023-11-21
CA3118002A1 (en) 2020-05-07
CL2021001073A1 (es) 2021-11-12
US20200140514A1 (en) 2020-05-07
TWI749381B (zh) 2021-12-11
BR112021006782A2 (pt) 2021-07-13
TW202208410A (zh) 2022-03-01
AU2022231763B2 (en) 2024-05-09
PE20211466A1 (es) 2021-08-05
MX2021004930A (es) 2021-06-08
ECSP21030933A (es) 2021-05-31
CN112888705A (zh) 2021-06-01
CO2021005514A2 (es) 2021-05-10
KR20210071038A (ko) 2021-06-15
AU2022231763A1 (en) 2022-10-06
IL282177A (en) 2021-05-31
JP2022506070A (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
ECSP21030933A (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
CL2022000178A1 (es) Análogos de relaxina y métodos para usarlos
CO2020014180A2 (es) Derivados de gip y usos de estos
PE20160683A1 (es) Analogos de glucagon acilados
PE20210162A1 (es) Analogos de incretina y sus usos
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CL2019001552A1 (es) Agonistas duales acilados de glp-1/glp-2.
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
CL2019003660A1 (es) Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2).
CO2018002328A2 (es) Formulaciones que comprenden variantes de péptido natriurético de tipo c (cnp)
GT200500235A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos
AR103246A1 (es) Derivados de fgf21 y sus usos
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
AR116451A1 (es) Administración oral de análogos del péptido glp-1
CL2023002583A1 (es) Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos.
AR116803A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
AR120440A1 (es) Agonistas del receptor npy2
PE20221518A1 (es) Analogos de incretina y sus usos
CO2023009085A2 (es) Pauta posológica de levodopa
AR114080A1 (es) Anticuerpos pac1 y sus usos
CO2022011101A2 (es) Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismos